Why all the buzz about biosimilars?
Biosimilars, also known as follow-on biologics, are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods. The evolving biosimilars landscape is of concern to companies here in the U.S. and worldwide.
Next week, the Gibbons Institute of Law, Science & Technology will be hosting “Navigating the Biosimilars Landscape,” on February 19, 2013, from 4:30 – 7:00 pm at the Seton Hall Law School in Newark, NJ. This program will provide a look at biosimilar legislation and legal aspects relating to biosimilars, as well as considerations and strategies for both innovator and biosimilar companies.
Panelists for this program include Reza Green, Vice President of Intellectual Property for Novo Nordisk, Inc.; Jordan Paradise, Associate Professor of Law at Seton Hall University School of Law; and Estelle J. Tsevdos, Ph.D.; George M. Gould and Lisa H. Wang of the Gibbons Intellectual Property Department. The panel will discuss litigation under the Biologics Price Competition and Innovation Act (BPCI), state-based legislation affecting biosimilars and the Food and Drug Administration’s regulation of biosimilars.
Registration for the program starts at 4:30 pm, with the panel discussion at 5:00 pm and a networking reception following the program at 7:00 pm. The $30 program fee includes food, beverages, parking and 2.0 NY & NJ CLE Credits.